N-(4-methylphenyl)maleamic acid | 37904-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-methylphenyl)maleamic acid
• 英文别名: 3-p-tolylcarbamoyl-acrylic acid；4-oxo-4-(p-tolylamino)but-2-enoic acid；p-TMA；p-tolylmaleamic acid；(Z)-4-[(4-methylphenyl)amino]-4-oxo-2-butenoic acid；N-p-Tolyl-maleamidsaeure；N-p-tolyl-maleamic acid；Maleinsaeure-mono-p-toluidid；N-p-Tolyl-maleinamidsaeure；(2E)-4-oxo-4-(4-toluidino)-2-butenoic acid；4-(4-methylanilino)-4-oxobut-2-enoic acid
• CAS: 37904-03-3
• 化学式: C₁₁H₁₁NO₃
• mdl: MFCD00174100
• 分子量: 205.213
• InChiKey: VLWFSWMZGGZHGD-UHFFFAOYSA-N

物化性质

• 熔点：
  205 °C
• 沸点：
  446.0±45.0 °C(Predicted)
• 密度：
  1.282±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 安全说明：
  S26,S37/39

SDS

Name:	4-Oxo-4-(4-toluidino)but-2-enoic acid 97% Material Safety Data Sheet
Synonym:	N-(4-Methylphenyl)maleamic aci
CAS:	37904-03-3

Section 1 - Chemical Product MSDS Name:4-Oxo-4-(4-toluidino)but-2-enoic acid 97% Material Safety Data Sheet
Synonym:N-(4-Methylphenyl)maleamic aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37904-03-3	4-Oxo-4-(4-toluidino)but-2-enoic acid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37904-03-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 205 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11NO3
Molecular Weight: 205

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37904-03-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Oxo-4-(4-toluidino)but-2-enoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 37904-03-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 37904-03-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37904-03-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(4-methylphenyl)maleamic acid 在 dirhodium tetraacetate 、 sodium acetate 作用下， 以 乙酸酐 、 1,2-二氯乙烷 为溶剂， 反应 0.5h， 生成 (1R,3aR,6aS)-1-(4-ethoxyphenyl)-5-(4-methylphenyl)spiro[3a,6a-dihydro-1H-furo[3,4-c]pyrrole-3,2'-indene]-1',3',4,6-tetrone
  参考文献：
  名称：

  通过虚拟筛选结合生物学评估，发现，设计和合成2型腺苷酸环化酶有效激动剂。

  摘要：

  腺苷酸环化酶（AC）在三磷酸腺苷（ATP）转化为第二信使环单磷酸腺苷（cAMP）的过程中起关键作用。研究表明2型腺苷酸环化酶（AC2）是许多疾病的潜在药物靶标，但是，到目前为止，尚无AC2选择性激动剂的报道。在这项研究中，已经进行了基于对接的虚拟筛选与基于细胞的生物学检测相结合，以发现新型有效的和选择性的AC2激动剂。虚拟筛选揭示了一种新型的命中化合物8，作为AC2激动剂，在重组人hAC2 + HEK293细胞上的EC50值为8.10μM。在重组AC2细胞上进一步研究了基于化合物8衍生物的SAR（结构活性关系），发现化合物73是最具活性的激动剂，EC50为90 nM，它比报道的激动剂福斯高林强160倍，并且可以选择性激活AC2以抑制白介素6的表达。新型AC2选择性激动剂的发现将为研究AC2的生理功能提供一种新颖的化学探针。

  DOI：

  10.1016/j.ejmech.2020.112115
• 作为产物：
  描述：

  马来酸酐 、 乙烷,三氯氟- 以 1,4-二氧六环 为溶剂， 反应 0.75h， 生成 N-(4-methylphenyl)maleamic acid
  参考文献：
  名称：

  （NH4）2S2O8-DMSO自由基介导的环状酰亚胺脱水制备：在vernakalant合成中的应用。

  摘要：

  过硫酸铵-二甲基亚砜（APS-DMSO）已开发为一种高效的新型脱水剂，可用于方便的一锅法合成杂环状酰亚胺的便捷方法，从容易获得的伯胺和环状酸酐开始就可以高收率地合成。已经提出了涉及DMSO的可能的自由基机制。已经证明了这种简便的一锅式酰亚胺形成方法在实际合成vernakalant中的应用。

  DOI：

  10.3762/bjoc.11.113

文献信息

• Chemoselective Acylation of Amines in Aqueous Media
  作者：Sarala Naik、Gitalee Bhattacharjya、Bandana Talukdar、Bhisma K. Patel

  DOI：10.1002/ejoc.200300620

  日期：2004.3

  Amines are efficiently acylated by both cyclic and acyclic anhydrides by dissolving them in an aqueous medium with the help of a surfactant, sodium dodecyl sulfate (SDS). Cyclic and acyclic anhydrides react with equal ease with an amine, and amines with various stereo-electronic factors react at the same rates with an anhydride. Chemoselective acylation of amines in the presence of phenols and thiols

  通过在表面活性剂十二烷基硫酸钠 (SDS) 的帮助下将胺溶解在水性介质中，胺被环状酸酐和无环酸酐有效地酰化。环状和无环酸酐与胺反应同样容易，具有各种立体电子因子的胺与酸酐以相同的速率反应。已经实现了在酚类和硫醇存在下胺的化学选择性酰化以及在酚存在下硫醇的化学选择性酰化。反应过程中不使用酸性或碱性试剂。分离酰化产物不需要色谱分离。在中性水性介质中反应，产物容易分离，副产物无害，使本方法成为一种绿色化学过程。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004)
• Solvent-mediated One-pot Synthesis of Cyclic<i>N</i>-Substituted Imides
  作者：Sambhaji V. Patil、Keshao A. Mahale、Kirankumar S. Gosavi、Ganesh B. Deshmukh、Nilesh S. Patil

  DOI：10.1080/00304948.2013.798569

  日期：2013.7.4

  synthesized by elaboration of N-aryl maleimides.16–19 Evaluation of the available methods for the synthesis of N-substituted cyclic imides indicates that generally the amines are first reacted with the desired cyclic anhydride and the resulting amic acids are then cyclized to the corresponding imides using reagents such as Ac2O/NaOAc, Et3N/Ac2O, dimethyl sulfate/Na2CO3/tetrabutylammonium bromide,27 cyanuric

  从现成的试剂中开发通用、高效的有机化合物合成方法是有机合成中的挑战之一。N-取代的环状酰亚胺在生物学、1-6 药理学、7 合成化学、8-19 聚合物化学、20,21 和材料科学中有许多应用。22,23 几种除草剂、24 杀虫剂、24 和抗真菌剂 1 以及宿主还通过精心设计 N-芳基马来酰亚胺合成了许多具有生物活性的天然产物。 16-19 对合成 N-取代环状酰亚胺的可用方法的评估表明，通常胺类首先与所需的环状酸酐反应，然后生成酰胺然后使用诸如 Ac2O/NaOAc、Et3N/Ac2O、硫酸二甲酯/Na2CO3/四丁基溴化铵等试剂将酸环化为相应的酰亚胺，27 氰尿酰氯/Et3N、[Bmim] [PF6]、140°C29 等。30-35 然而，其中一些程序 i) 缺乏通用性和可扩展性，ii) 使用苛刻的反应条件和危险的非绿色试剂， iii) 涉及繁琐的后处理和昂贵的试剂，iv) 产率低，有时会导致
• SPIROCYCLIC COMPOUNDS CONTAINING SPIRO[INDOLYL-3,1'-PYRROLO[3,4-C]PYRROLE] CORE AND SULPHUR-CONTAINING AMINO ACID RESIDUES
  申请人：ZAGORII Gleb Vladimirovich

  公开号：US20160297828A1

  公开（公告）日：2016-10-13

  The present invention relates to spirocyclic compounds on the basis of 2-oxindole derivatives containing a spiro[indolyl-3,1′-pyrrolo[3,4-c]-pyrrole] core and biogenic sulphur-containing amino acid residues, which display a glucocorticoid-mimicking action by influencing 11β-HSD1 enzyme cortisone->cortisol conversion, or by inhibiting GRs- or GITR- or mineralocorticoid receptors, or other targets, but do not interfere with steroidal haemostasis in HPA; and compositions containing same and their use for therapy as part of undifferentiated stroke therapy (in the absence of final verification of the stroke subtype) at various stages of acute ischemic stroke (AIS), during the period of recovery from stroke and craniocerebral trauma, in patients with chronic cerebrovascular pathology (against a background of diabetes), in combinational therapy for Alzheimer's disease and encephalopathy of various origin (discirculatory, alcoholic, infectious-toxic), and diabetes, combinational therapy for retinal degenerative eye diseases, as part of combinational therapy for metabolic syndrome (obesity, in patients suffering from Cushing's syndrome, Reaven metabolic syndrome (also known as syndrome X or insulin resistance syndrome) and other diseases where GCs hormones play a key role.

  本发明涉及基于2-氧吲哚衍生物的螺环化合物，含有螺[吲哚基-3,1′-吡咯[3,4-c]-吡咯]核和含生物硫氨基酸残基，通过影响11β-HSD1酶的皮质醇->皮质酮转化，或通过抑制GRs-或GITR-或矿物皮质激素受体或其他靶点，但不干扰HPA中的类固醇止血作用，表现出类固醇激素模拟作用；以及含有相同化合物的组合物及其在治疗中的用途，作为未分化中风治疗的一部分（在未最终验证中风亚型的情况下），在急性缺血性中风（AIS）的各个阶段，中风康复期间和颅脑创伤期间，对患有慢性脑血管病变（伴有糖尿病）的患者，对阿尔茨海默病和各种起源的脑病（循环障碍性、酒精性、感染性-毒性）和糖尿病的组合疗法，对视网膜退行性眼病的组合疗法，作为代谢综合征的组合疗法的一部分（肥胖症，在患有库欣综合征、Reaven代谢综合征（也称为X综合征或胰岛素抵抗综合征）和其他类固醇激素起关键作用的疾病患者）。
• Design, synthesis and biological evaluation of novel 3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase inhibitors and antifungal agents
  作者：Baihui Li、Yangli Shen、Hu Wu、Xiaobo Wu、Lvjiang Yuan、Qinggang Ji

  DOI：10.1016/j.ejmech.2020.112278

  日期：2020.6

  A series of 3,4-dihydro-2(1H)-quinolinone derivatives contained butenediamide fragment were designed and synthesized. Their inhibition potency against chitin synthase and antimicrobial activities were screened in vitro. The enzymatic assays showed that all the synthesized compounds had inhibition potency against chitin synthase at concentration of 300 μg/mL. Compound 2d displayed excellent potency

  设计合成了一系列含有丁烯二酰胺片段的3,4-二氢-2（1H）-喹啉酮衍生物。在体外筛选了它们对几丁质合酶的抑制能力和抗菌活性。酶促测定表明，所有合成的化合物在300μg/ mL的浓度下均具有针对甲壳质合酶的抑制能力。化合物2d表现出优异的效能，抑制百分数（IP）值为82.3％，而对照多恶菌素B的IP值为87.5％。IP值高于70％的化合物2b，2e和2s显示出对几丁质合酶的良好抑制能力。此外，2b的IC50值可与多恶英B（0.09 mM）相媲美。化合物2b的Ki为0.12 mM，Lineweaver-Burk图的结果表明2b是与甲壳质合酶结合的非竞争性抑制剂。抗真菌实验表明，这些化合物对真菌菌株，特别是白色念珠菌具有优异的抗真菌活性。化合物2b，2d，2e和2l对白念珠菌的抗真菌活性与氟康唑相当，并且优于多恶灵B。同时，其他化合物对白念珠菌的抗真菌活性也更好（MIC 2μg/ mL ）比化合物2n（MIC
• Design, Synthesis and Biochemical Evaluation of Novel Ethanoanthracenes and Related Compounds to Target Burkitt’s Lymphoma
  作者：Andrew J. Byrne、Sandra A. Bright、James P. McKeown、John E. O’Brien、Brendan Twamley、Darren Fayne、D. Clive Williams、Mary J. Meegan

  DOI：10.3390/ph13010016

  日期：——

  Burkitt’s lymphoma (BL) is a rare form of non-Hodgkin’s lymphoma in which the cancer starts in the immune B-cells. We report the synthesis and preliminary studies on the antiproliferative activity of a library of 9,10-dihydro-9,10-ethanoanthracene based compounds structurally related to the antidepressant drug maprotiline against BL cell lines MUTU-1 and DG-75. Structural modifications were achieved by Diels-Alder

  淋巴瘤（淋巴系统癌）占全世界恶性疾病的12％。伯基特氏淋巴瘤（BL）是非霍奇金淋巴瘤的一种罕见形式，其癌症始于免疫B细胞。我们报告了9,10-dihydro-9,10-ethanananthracene基化合物与抗抑郁药Maprotiline对BL细胞系MUTU-1和DG-75结构相关的化合物的合成和抗增殖活性的初步研究。通过使9-（2-硝基乙烯基）蒽核心与许多亲二烯体包括马来酸酐，马来酰亚胺，丙烯腈和苯炔的狄尔斯-阿尔德反应进行结构修饰。在BL细胞系EBV- MUTU-1和EBV + DG-75（耐化学性）中评估了这些化合物的抗增殖活性。最有效的化合物13j，15、16a，16b，16c，图16d和19a显示的相对于BL细胞系EBV- MUTU-1的IC50值在0.17–0.38μM范围内，相对于耐化学性BL细胞系EBV + DG-75的IC50值在0.45–0.78μM范围内。化合物1